NASDAQ:MGNX - MacroGenics Stock Price, Forecast & News

MacroGenics' stock was trading at $6.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MGNX shares have decreased by 19.4% and is now trading at $5.23. View which stocks have been mosted impacted by Coronavirus.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 sell rating, 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MacroGenics.

MacroGenics is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for MacroGenics.

MacroGenics Inc (NASDAQ:MGNX) issued its quarterly earnings data on Tuesday, February, 25th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.71) by $0.10. The biopharmaceutical company had revenue of $25.19 million for the quarter, compared to analysts' expectations of $10.74 million. MacroGenics had a negative return on equity of 55.16% and a negative net margin of 236.51%. View MacroGenics' earnings history.

12 brokers have issued 1 year target prices for MacroGenics' stock. Their forecasts range from $6.00 to $50.00. On average, they expect MacroGenics' share price to reach $18.91 in the next twelve months. This suggests a possible upside of 261.6% from the stock's current price. View analysts' price targets for MacroGenics.

Press coverage about MGNX stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MacroGenics earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutMacroGenics.

MacroGenics saw a drop in short interest in February. As of February 28th, there was short interest totaling 3,670,000 shares, a drop of 5.2% from the February 13th total of 3,870,000 shares. Based on an average trading volume of 486,000 shares, the days-to-cover ratio is presently 7.6 days. Currently, 8.5% of the shares of the company are short sold. View MacroGenics' Current Options Chain.

Some companies that are related to MacroGenics include Amneal Pharmaceuticals (AMRX), Enanta Pharmaceuticals (ENTA), Y-mAbs Therapeutics (YMAB), TG Therapeutics (TGTX), Akebia Therapeutics (AKBA), Phibro Animal Health (PAHC), NextCure (NXTC), Madrigal Pharmaceuticals (MDGL), Supernus Pharmaceuticals (SUPN), Aimmune Therapeutics (AIMT), Opko Health (OPK), Kiniksa Pharmaceuticals (KNSA), Odonate Therapeutics (ODT), Endo International (ENDP) and Esperion Therapeutics (ESPR).

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Gilead Sciences (GILD), NVIDIA (NVDA), TherapeuticsMD (TXMD), Incyte (INCY), Karyopharm Therapeutics (KPTI), Nektar Therapeutics (NKTR) and TG Therapeutics (TGTX).

MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."

Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MGNX stock can currently be purchased for approximately $5.23.

MacroGenics has a market capitalization of $256.95 million and generates $64.19 million in revenue each year. The biopharmaceutical company earns $-151,810,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. MacroGenics employs 364 workers across the globe. View additional information about MacroGenics.

The official website for MacroGenics is http://www.macquarie.com/.

MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.